About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
K
Panel Case Discussion: 56 y/o Female With DCIS L Breast
By
UChicago Medicine 12th International Clinical Cancer Genomics Conference
FEATURING
Kara Maxwell
,
Stacy Gray
,
Nora Jaskowiak
,
Jeremy Segal
,
David VanderWeele
,
Olufunmilayo Olopade
,
Rodrigo Guindalini
By
UChicago Medicine 12th International Clinical Cancer Genomics Conference
FEATURING
Kara Maxwell
,
Stacy Gray
,
Nora Jaskowiak
,
Jeremy Segal
,
David VanderWeele
,
Olufunmilayo Olopade
,
Rodrigo Guindalini
0 views
May 26, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
06:14
Lilly Medical Affairs
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
Feat.
J. O’Shaughnessy
Featured Video
02:58
Lilly Medical Affairs
A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC
Feat.
J. O’Shaughnessy
Recommended
AUTOPLAY
ON
Related
Newest
11:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …
Feat.
P. Tarantino
12:14
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…
Feat.
P. Tarantino
07:23
Total Health
Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…
Feat.
R. O'Regan
03:40
Integrity CE
SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …
Feat.
A. Bardia
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
28:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
17:39
Yale School of Medicine
2023 Menopause Update
Feat.
M. Minkin
09:19
Insights from 2023 SABCS
SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for…
Feat.
K. Kalinsky
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
05:43
Total Health
Neoadjuvant Chemo for HR+ BC: Year in Review
Feat.
C. Ma
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
09:55
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…
Feat.
E. Hamilton
10:34
Sara Tolaney
ASCO® 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
27:04
Fengting Yan
Cancer Screening Molecular Tools
22:34
Dana-Farber Cancer Institute
What's New in Breast Cancer?
Feat.
S. Tolaney
17:50
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…
Feat.
G. Sonpavde
21:01
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cance…
Feat.
S. Tolaney,
H. Rugo
10:27
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…
Feat.
S. Tolaney,
H. Rugo
36:18
Insights from ESMO Breast 2024 Annual Meeting
Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…
Feat.
H. Rugo
04:28
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …
Feat.
S. Tolaney
